A Two-Handed Technique in Biportal Endoscopic Spine Surgery Using an Endoscopic Self-Retractor for Resection of Ossification of Ligamentum Flavum in Thoracic Spine.

Clin Spine SurgJul 14, 2026 (epub)
Case ReportNeurosurgeryOrthopedic Surgery

Dong Hwa Heo, Ji Yeon Kim

✦ AI-curated · Sources linked

Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.

From the abstract

Biportal endoscopic spine surgery commonly employs a single-handed technique despite the presence of dual portals. An endoscopic self-retractor attached to the viewing trocar enables true bimanual manipulation. The adoption of this 2-handed technique enables safer, more effective resection of the thoracic ossification of the ligamentum flavum (OLF).

Authors' conclusions

The use of an endoscopic self-retractor for 2-handed manipulation enhances surgical precision and facilitates safer, more effective OLF removal. This technique improves control and safety during complex thoracic decompression.

Source

PubMed · PMID 42606351

Published in Clin Spine Surg. The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurosurgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.